Frontline antibiotic therapy

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 13, Issue 3, 2013, Pages 263-268

  MacGowan, Alasdair ^a   Albur, Maha ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Antibiotic resistance; Antibiotic therapy; Stewardship

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAMASE; CARBAPENEMASE; CEFEPIME; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; DOXYCYCLINE; ERYTHROMYCIN; FOSFOMYCIN; GENTAMICIN; LINEZOLID; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; PRISTINAMYCIN; STREPTOGRAMIN DERIVATIVE; TELAVANCIN; TEMOCILLIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BACTERICIDAL ACTIVITY; BURKHOLDERIA CEPACIA; CHLAMYDIASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; ENDOCARDITIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; KLEBSIELLA PNEUMONIAE; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MORGANELLA; MULTICENTER STUDY (TOPIC); MYALGIA; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PROTEIN BINDING; SERRATIA; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; THROMBOPHLEBITIS; UNITED KINGDOM; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL INFECTION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; MULTIDRUG RESISTANCE; REVIEW; STEWARDSHIP;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; STEWARDSHIP;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENGLAND; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 84884519552     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.13-3-263     Document Type: Article

References (60)

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929;10:226-36.
2. Falconer SB, Czarny TL, Brown ED. Antibiotics as probes of biological complexity. Nat Chem Biol 2011;7:415-23.
3. Swartz MN. Bacterial meningitis - a view of the past 90 years. N Engl J Med 2004;351:1826-8.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic 2010. Geneva: UNAIDS, 2010. www.unaids.org/globalreport/ global-report.htm) [Accessed 7 April 2013].
5. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64:i29-36.
6. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
7. Theuretzbacher U. Accelerating resistance, inadequate antibacterial drug pipelines and international responses. Int J Antimicrob Agents 2012;39:295-9.
8. MacGowan AP. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother, 2008;62:ii105-14.
9. World Health Organization. Policy package to combat antimicrobial resistance. Geneva: WHO, 2011. www.who.int/world-health-day/2011/presskit/ WHDIntrototobriefs.pdf[Accessed 7 April 2013].
10. European Medicines Agency. European Antibiotic Awareness Day: 18 November 2011. London: EMEA, 2011. www.ema.europa.eu/ema/index.jsp?curl=pages/news-and- events/news/2011/11/news-detail-001383.jsp&mid=WC0b01ac058004d5c1& jsenabled=true [Accessed 7 April 2013].
11. Paul M, Shani V, Muchtar E et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851-63.
12. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
13. British Society for Antimicrobial Chemotherapy. www.bsacsurv.org[Accessed 7 April 2013].
14. Farrell DJ, Felmingham D, Shackcloth J et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community- acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 2008;62:ii87-95.
15. Martin V, Maher K, Morrissey I, Reynolds R. BSAC respiratory resistance surveillance update 2009/10. Poster presented at the Federation of Infection Societies (FIS) Scientific Meeting, Manchester, UK, 16-18 November 2011 (Poster P0136).
16. European Centre for Disease Prevention and Control. EARS-Net database. Stockholm: eCDC, 2011. ecdc.europa.eu/en/activities/surveillance/EARS-Net/ database/Pages/database.aspx [Accessed 7 April 2013].
17. Henderson KL, Muller-Pebody B, Blackburn RM, Johnson AP. Reduction in erythromycin resistance in invasive pneumococci from young children in England and Wales. J Antimicrob Chemother 2010;65:369-70.
18. Birtles A, Virgincar N, Sheppard CL et al. Antimicrobial resistance of invasive Streptococcus pneumoniae isolates in a British district general hospital: the international connection. J Med Microbiol 2004;53:1241-6.
19. Martin V, Hope R, Livermore DM, Reynolds R. BSAC bacteraemia resistance surveillance update 2010. Poster presented at the Federation of Infection Societies (FIS) Scientific Meeting, Manchester, UK, 16-18 November 2011 (Poster P0135).
20. Brown DF, Hope R, Livermore DM et al. Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008;62:ii75-85.
21. Health Protection Agency. Summary points on meticillin resistant Staphylococcus aureus (MRSA) bacteraemia. London: HPA, 2012. www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1278944283762 [Accessed 7 April 2012].
22. Hope R, Livermore DM, Brick G et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001- 06. J Antimicrob Chemother 2008;62:ii65-74.
23. Reynolds R, Hope R, Warner M. BSAC bacteraemia resistance surveillance - no upward creep in MRSA vancomycin MICs. Poster presented at the Federation of Infection Societies (FIS) Scientific Meeting, Manchester, UK, 16-18 November 2011 (Poster P22).
24. Kirby A, Graham R, Williams NJ et al. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother 2010;65:721-4.
25. Livermore DM, Hope R, Brick G et al. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008;62:ii41-54.
26. Reynolds R, Hope R. Stabilization in prevalence of ESBLs and ciprofloxacin non-susceptibility in Enterobacteriaceae from blood in the UK and Ireland. Abstract presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 10-13 April 2010 (Abstract O135).
27. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.
28. Woodford N. ARMRL news: winter 2012. London: Health Protection Agency, 2012.
29. Pulcini Cl, Bush K, Craig WA et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012;54:268-74.
30. Garonzik SM, Li J, Thamlikitkul V, Paterson DL et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94.
31. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77.
32. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis 2010;10:43-50.
33. Wootton M, Walsh TR, Macfarlane L, Howe RA. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010;65:79-81.
34. Thomas K, Weinbren MJ, Warner M et al. Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 2006;57:367-8.
35. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010;65:iii25-33.
36. Rodríguez-Baño J, Navarro MD, Retamar P et al. β-lactam/β -lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β -lactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167-74.
37. Reid AB, Daffy JR, Stanley P, Buising KL. Use of pristinamycin for infections by Gram-positive bacteria: clinical experience at an Australian hospital. Antimicrob Agents Chemother 2010;54:3949-52.
38. Stein EG. Safety of newer parenteral antibiotics. Clin Infect Dis 2005;41:S293-S302.
39. Slocombe B, Basker MJ, Bentley PH et al. BRL 17421 a novel beta-lactam antibiotic highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother 1981;20:38-46.
40. Balakrishnan I, Awad-El-Kariem FM, Aali A et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamaseproducing Enterobacteriaceae. J Antimicrob Chemother 2011;66:2628-31.
41. Daniels JM, Snijders D, de Graaff CS et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010:181:150-7.
42. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006;57:589-608.
43. Stein A, Bataille JF, Drancourt M et al. Ambulatory treatment of multidrug- resistant staphylococcus-infected orthopedic implants with highdose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998;2:3086-91.
44. Kunkel M, Chastre JE, Kollef M et al. Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillinresistant Staphylococcus aureus. Abstract presented at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, BC, Canada, 10-13 April 2010 (Abstract LB-49).
45. Wunderink RG, Rello J, Cammarata SK et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97.
46. Kohno S, Yamaquchi K, Aikawa N et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007;60:1361-9.
47. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-6.
48. Stevens DL, Herr D, Lampiris H et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90.
49. Gould FK, Denning DW, Elliott TS et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012;67:269-89.
50. Fowler VG, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
51. Novartis Pharmaceuticals UK. Summary of product characterstics: cubicin powder for concentrate for solution for injection or infusion. Camberley: Novartis Pharmaceuticals UK, 2012. www.medicines.org.uk/EMC/medicine/17341/SPC/ Cubicin+powder+for+concentrate+for+solution+for+injection+or+infusion/ #INDICATIONS [Accessed 7 April 2013].
52. Rubinstein E, Lalani T, Corey GR et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. Clin Infect Dis 2011;52:31-40.
53. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-38.
54. Freire AT, Melnyk V, Kim MJ et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51.
55. Cai Y, Wang R, Liang B et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55:1162-72.
56. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: A meta-analysis. Lancet Infect Dis 2011;11:834-44.
57. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8.
58. Nordmann P, Picazo JJ, Mutters R et al. Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 2011;66:1070-8.
59. ClinicalTrials.gov. Doripenem in the treatment of hospital-acquired pneumonia. Bethesda: US National Institutes of Health, 2012.
60. Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI). Antimicrobial stewardship: 'Start smart - then focus': guidance for antimicrobial stewardship in hospitals (England). London: Department of Health, 2011.